Document text
Principal Investigator: Norbert Pardi
Organization: UNIVERSITY OF PENNSYLVANIA
Fiscal Year: 2023
Award: $708,799
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT
Vaccines prevent hundreds of millions of illnesses and save millions of lives every year. Various types of
licensed vaccines (live attenuated and inactivated pathogens, adjuvanted protein subunits) provide some level
of protection against a variety of dangerous illnesses. However, there are multiple pathogens for which no
effective vaccines are available. Protective immunity against many pathogens can be achieved through long-
lived and high-affinity antibody responses, which are driven by T follicular helper (Tfh) cells. Tfh cells are
required for the formation and maintenance of germinal centers (GC), where B cell affinity maturation, class
switch, and development of long-lived plasma and memory B cells occur. Thus, the magnitude or quality of
antibody responses induced by a vaccine is shaped by its ability to induce Tfh cells. The identification of
vaccine platforms or adjuvants that induce potent Tfh cell responses and broadly protective and durable
antibody responses is a critical need in vaccinology. We have identified a potent vaccine adjuvant, lipid
nanoparticles (LNPs), which induce strong Tfh cell differentiation and durable antibody responses after a single
immunization when combined with protein subunits, inactivated virus or antigen-encoding mRNA. Importantly,
our preliminary studies demonstrated the superiority of LNP's adjuvant activity over the FDA-approved vaccine
adjuvant, MF59, in comparative studies. This proposal will aim to extend our preliminary findings, examine
LNP's adjuvanticity in non-human primate immunization studies and investigate the mechanisms of action of
LNPs. In 3 specific aims we will: 1.) Determine LNP's adjuvanticity in multiple vaccine platforms in mice. 2.)
Assess the potency of LNP-adjuvanted Zika vaccines in non-human primates. 3.) Uncover LNP-induced
immune mechanisms that regulate the biology of Tfh cells.
This proposal aims to demonstrate that LNPs can be used as adjuvants in various conventional (inactivated
pathogen and protein subunits) and unconventional (mRNA, DNA) vaccine types to induce strong Tfh cell and
durable neutralizing antibody responses. This finding could have a significant impact on vaccine development
as no licensed vaccines or adjuvants have been shown to potently activate Tfh cells that are critical for durable
protective antibody responses against many pathogens. We believe that the data generated in this proposal
will be capable of moving this vaccine adjuvant towards clinical trials.
Terms: <Adjuvant><Adjuvanticity><Affinity><Alum Adjuvant><Animal Model><Animal Models and Related Studies><Animals><Antibody Affinity><Antibody Response><Antigens><Assay><Atlases><Attenuated><Automobile Driving><B blood cells><B cell><B cell repertoire><B cells><B-Cells><B-Lymphocytes><B-cell><Binding><Bioassay><Biologic Assays><Biological Assay><Biology><Blood Plasma><Blood Plasma Cell><Cell Body><Cell Communication and Signaling><Cell Differentiation><Cell Differentiation process><Cell Signaling><Cells><Cellular biology><Class Switching><Class Switchings><Clinical Trials><Communicable Diseases><Comparative Study><DNA><DNA Vaccines><Dangerousness><Data><Dendritic Cells><Deoxyribonucleic Acid><Development><Dose><ELISA><Effectiveness><Encapsulated><Endowment><Enzyme-Linked Immunosorbent Assay><FDA approved><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Germinal Center><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><Hemagglutination><Human><Immune><Immune response><Immunes><Immunity><Immunization><Immunoglobulin Class Switching><Immunoglobulin Class Switchings><Immunological response><In Vitro><Inactivated Vaccines><Inactivated Virus Vaccine><Inducer Cells><Inducer T-Lymphocytes><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza Vaccines><Interferon Type I><Intracellular Communication and Signaling><Isotype Switching><Isotype Switchings><Killed Vaccines><Kinetics><Knowledge><Licensing><Ligands><M mulatta><M. mulatta><MF59><Macaca mulatta><Maintenance><Maps><Measures><Memory B Cell><Memory B-Lymphocyte><Messenger RNA><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Interaction><Murine><Mus><Naked DNA Vaccines><Nucleosides><Plasma><Plasma Cells><Plasma Serum><Plasmacytes><Protein Subunits><Proteins><Reaction><Receptor Protein><Recombinant DNA Vaccines><Reticuloendothelial System, Serum, Plasma><Rhesus Macaque><Rhesus Monkey><Route><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Structure of germinal center of lymph node><Subunit Vaccines><Testing><Vaccine Adjuvant><Vaccines><Veiled Cells><Viral Diseases><Virus><Virus Diseases><ZIKV vaccine><Zika vaccine><Zika virus vaccine><access to vaccination><access to vaccines><adaptive immune response><alum><aluminum sulfate><antigen antibody affinity><attenuate><attenuates><biological signal transduction><candidate identification><cell biology><comparative><develop a vaccine><develop vaccines><development of a vaccine><developmental><driving><enzyme linked immunoassay><evaluate vaccines><experience><experiment><experimental research><experimental study><experiments><flow cytophotometry><flu vaccine><flu virus vaccine><gene signatures><genetic signature><host response><immune system response><immunogen><immunoresponse><influenza virus vaccine><lipid based nanoparticle><lipid nanoparticle><mRNA><model of animal><neutralizing antibody><new vaccines><next generation vaccines><non-human primate><nonhuman primate><novel><novel vaccines><pathogen><plasmid DNA><plasmocyte><prevent><preventing><rational design><receptor><response><transcriptomics><vaccination access><vaccination availability><vaccination study><vaccination trial><vaccine access><vaccine against flu><vaccine against influenza><vaccine availability><vaccine development><vaccine evaluation><vaccine platform><vaccine screening><vaccine study><vaccine testing><vaccine trial><vaccinology><viral infection><virus infection><virus-induced disease>